Circulating Anti-Rituximab Antibodies Do Not Affect Response to Rituximab in Steroid-Dependent Nephrotic Syndrome

Andrea Angeletti; Maurizio Bruschi; Manuela Colucci; Xhuliana Kajana; Edoardo La Porta; Gianluca Caridi; Francesca Lugani; Pietro Ravani; Marina Vivarelli; Paolo Cravedi; Gian Marco Ghiggeri

doi:10.1016/j.ekir.2022.08.006

Circulating Anti-Rituximab Antibodies Do Not Affect Response to Rituximab in Steroid-Dependent Nephrotic Syndrome

Andrea Angeletti, Maurizio Bruschi, Manuela Colucci, Xhuliana Kajana, Edoardo La Porta, Gianluca Caridi, Francesca Lugani, Pietro Ravani, Marina Vivarelli, Paolo Cravedi, Gian Marco Ghiggeri

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Original language	English
Pages (from-to)	2509-2512
Number of pages	4
Journal	Kidney International Reports
Volume	7
Issue number	11
DOIs	https://doi.org/10.1016/j.ekir.2022.08.006
State	Published - Nov 2022

Keywords

anti-rituximab antibodies
focal segmental glomerulosclerosis
monoclonal anti-CD20 antibodies
nephrotic syndrome
rituximab
steroid-dependent nephrotic syndrome

Access to Document

10.1016/j.ekir.2022.08.006

Cite this

@article{0c0985a0a4754f9987189b0d03f0ba8a,

title = "Circulating Anti-Rituximab Antibodies Do Not Affect Response to Rituximab in Steroid-Dependent Nephrotic Syndrome",

keywords = "anti-rituximab antibodies, focal segmental glomerulosclerosis, monoclonal anti-CD20 antibodies, nephrotic syndrome, rituximab, steroid-dependent nephrotic syndrome",

author = "Andrea Angeletti and Maurizio Bruschi and Manuela Colucci and Xhuliana Kajana and {La Porta}, Edoardo and Gianluca Caridi and Francesca Lugani and Pietro Ravani and Marina Vivarelli and Paolo Cravedi and Ghiggeri, {Gian Marco}",

note = "Funding Information: This work was supported by the Italian Ministry of Health— Ministero della Salute , Ricerca Corrente 2022. Funding Information: This work was supported by the Italian Ministry of Health—Ministero della Salute, Ricerca Corrente 2022. The data sets generated for this study are available on request to the corresponding author. Study approval was obtained from the local independent ethics committee (ComitatoEticoRegione Liguria) and the Italian Drug Agency (Agenzia Italiana del Farmaco, AIFA). We registered the study at https://clinicaltrials.gov (study number: NCT02394119) and at https://eudract.ema.europa.eu (Eudract study number 2015-000624-28). AA and GMG contributed to the conception and design of the work. AA wrote the letter. PC largely revised the letter. PR and GMR designed the original trial. MB performed laboratory and statistical analysis. MC and MV performed laboratory analysis on B cells. AA, GC, FL, ELP, MC, MV, PC, and GMG revised it critically and contributed to the interpretation of data. All the authors provide approval for publication of the content.",

year = "2022",

month = nov,

doi = "10.1016/j.ekir.2022.08.006",

language = "English",

volume = "7",

pages = "2509--2512",

journal = "Kidney International Reports",

issn = "2468-0249",

publisher = "Elsevier Inc.",

number = "11",

}

TY - JOUR

T1 - Circulating Anti-Rituximab Antibodies Do Not Affect Response to Rituximab in Steroid-Dependent Nephrotic Syndrome

AU - Angeletti, Andrea

AU - Bruschi, Maurizio

AU - Colucci, Manuela

AU - Kajana, Xhuliana

AU - La Porta, Edoardo

AU - Caridi, Gianluca

AU - Lugani, Francesca

AU - Ravani, Pietro

AU - Vivarelli, Marina

AU - Cravedi, Paolo

AU - Ghiggeri, Gian Marco

N1 - Funding Information: This work was supported by the Italian Ministry of Health— Ministero della Salute , Ricerca Corrente 2022. Funding Information: This work was supported by the Italian Ministry of Health—Ministero della Salute, Ricerca Corrente 2022. The data sets generated for this study are available on request to the corresponding author. Study approval was obtained from the local independent ethics committee (ComitatoEticoRegione Liguria) and the Italian Drug Agency (Agenzia Italiana del Farmaco, AIFA). We registered the study at https://clinicaltrials.gov (study number: NCT02394119) and at https://eudract.ema.europa.eu (Eudract study number 2015-000624-28). AA and GMG contributed to the conception and design of the work. AA wrote the letter. PC largely revised the letter. PR and GMR designed the original trial. MB performed laboratory and statistical analysis. MC and MV performed laboratory analysis on B cells. AA, GC, FL, ELP, MC, MV, PC, and GMG revised it critically and contributed to the interpretation of data. All the authors provide approval for publication of the content.

PY - 2022/11

Y1 - 2022/11

KW - anti-rituximab antibodies

KW - focal segmental glomerulosclerosis

KW - monoclonal anti-CD20 antibodies

KW - nephrotic syndrome

KW - rituximab

KW - steroid-dependent nephrotic syndrome

UR - http://www.scopus.com/inward/record.url?scp=85138063948&partnerID=8YFLogxK

U2 - 10.1016/j.ekir.2022.08.006

DO - 10.1016/j.ekir.2022.08.006

M3 - Article

AN - SCOPUS:85138063948

SN - 2468-0249

VL - 7

SP - 2509

EP - 2512

JO - Kidney International Reports

JF - Kidney International Reports

IS - 11

ER -